Sign in to fuzzto save your conversations, follow your research and come back anytime.
Indegene
SectorHealthcare
Indegene Limited is a global provider of digital-led commercialization services for the life sciences industry. The company offers solutions in analytics, technology, and commercial, medical, regulatory, and safety services to biopharmaceutical, emerging biotech, and medical devices companies. Indegene operates through four main segments: Enterprise Commercial Solutions, Omnichannel Activation, Enterprise Medical Solutions, and Others. These segments assist with digital marketing operations, last-mile promotion optimization, regulatory and medical operations consolidation, and clinical solutions and consultancy services. The company has made several acquisitions to expand its capabilities, including Encima Group, DT Associates, Cult Health, and Trilogy Writing & Consulting GmbH. In 2023, Indegene launched Invisage, an AI-enabled hybrid omnichannel sales and marketing platform. The company completed a public issue in May 2024, raising funds through a fresh issue and offer for sale.
In the news
Indegene Shares Hit 52-Week High at ₹621.90 on Axis Buy Rating
Indegene settles TCPA case for $4.72 million amid legal scrutiny
Indegene posts 30-40% growth, ₹3,511 cr revenue in FY26
Indegene Q1: 40% revenue jump, FY27 growth to beat 23-24%
Indegene Q3 revenue surges 31% to ₹942 crore despite profit decline
The Quarter story
The two most recent quarterly results, compared side-by-side.
Indegene expands its client base and recovers profitability, though rising costs and margin compression require monitoring.
Active clients expand from 70 in Q1 FY26 to 105 in Q1 2026-27, broadening the addressable customer base.
EBITDA margin softens from 20.2% in Q1 FY26 to 16.9% in Q1 2026-27, reflecting pricing and cost pressures.
Top 10 client concentration falls from 56.1% in Q1 FY26 to 45.7% in Q1 2026-27, reducing revenue dependency risk.
PAT margin falls from 15.3% in Q1 FY26 to 10.9% in Q1 2026-27, indicating ongoing profitability headwinds.
Profit after tax recovers from ₹797 Cr in Q4 FY26 to ₹1,162 Cr in Q1 2026-27, restoring bottom-line strength.
Employee benefit expenses rise from ₹4,815 Cr in Q1 FY26 to ₹6,591 Cr in Q1 2026-27, weighing on operating costs.
Revenue per employee rises from $70 in Q3 FY26 to $77 in Q1 2026-27, improving workforce productivity.
European revenue share declines from 27.1% in Q1 FY26 to 22.2% in Q1 2026-27, shifting geographic focus.
Voluntary attrition declines from 16.8% in Q1 FY26 to 15.7% in Q1 2026-27, stabilizing talent retention.
Other expenses climb from ₹1,240 Cr in Q1 FY26 to ₹2,298 Cr in Q1 2026-27, increasing operational overhead.
Company insights, generated from the most recent coverage.
Cash and investments of ₹14,602m against a debt-light balance sheet gives Indegene room to fund AI capability build or tuck-in acquisitions without diluting shareholders.
38.4% return over one year and 16.6% over six months means the margin-recovery story is already substantially priced in; Q3 FY27 results are the make-or-break test for the re-rating.
Stock up 3.45% to ₹614.60 on NSE, sitting just 0.15% below its 52-week high of ₹616 — breakout above that level would open fresh price discovery with no overhead supply.